Kilian Huber

Title: Kilian Huber: Innovator in Cancer Treatment

Introduction

Kilian Huber is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the development of compounds that can inhibit specific biological activities related to cancer.

Latest Patents

Kilian Huber holds a patent for "Aminoheteroaryl compounds as MTH1 inhibitors." This invention relates to an (S)-enantiomer of an aminoheteroaryl compound that is used for treating and/or preventing cancer in a subject. The patent also includes a pharmaceutical composition comprising this compound. Additionally, it describes an in vitro method for determining the effectiveness of the (S)-enantiomer or the pharmaceutical composition, which involves assessing the NUDT1/MTH1 status of a cell or tissue sample. The invention aims to identify effective treatments for cancer by targeting the biological activity of MTH1.

Career Highlights

Kilian Huber is associated with the CEMM Forschungszentrum für Molekulare Medizin GmbH, where he conducts his research. His work has led to advancements in understanding how specific compounds can be utilized in cancer therapies. He has demonstrated a commitment to improving treatment options for patients through innovative scientific research.

Collaborations

Kilian Huber collaborates with Giulio Superti-Furga, a fellow researcher in the field. Their partnership enhances the research efforts at CEMM and contributes to the development of new therapeutic strategies.

Conclusion

Kilian Huber's contributions to cancer treatment through his patented inventions highlight the importance of innovation in medical research. His work continues to pave the way for new therapeutic options that can significantly impact patient care.